Announcement PDF Starpharma CEO to retire in 2024 Melbourne, Australia; 9 June 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) wishes to advise that following her significant tenure as the Company’s Chief Executive Officer (CEO), Dr Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period. Starpharma Chair, Mr Rob Thomas commented: “On behalf of the Starpharma Board and all our staff, I respectfully acknowledge Jackie’s advice of her intention to retire and understand her desire to move on to the next chapter of her career in non-executive roles after more than 16 years as Chief Executive. Over her time as CEO Jackie has demonstrated a remarkable dedication to the Company’s development. Under her leadership and vision, Starpharma has successfully transformed from a startup with promising technology to a mature organisation with multiple commercial partnerships, marketed products around the world, and a strong portfolio of preclinical and clinical-stage assets. She has also built a stable and highly skilled workforce and positive organisational culture which will serve the Company well into the future. Jackie’s contribution to the Australian biotechnology industry is outstanding. I sincerely thank Jackie for her vision, leadership, drive, personal support and contribution throughout her time with Starpharma as CEO.” Jackie has agreed with the Board’s request to remain available under a consultancy agreement for a period of up to 12 months after her successor commences to provide Starpharma maximum flexibility for the transition. Dr Jackie Fairley said: “I am extremely proud of what we have achieved at Starpharma and am honoured to have served as Starpharma’s CEO since 2006. It has been a privilege to work with the incredibly talented and dedicated Starpharma team, and I strongly believe the Company has an exciting future ahead. It will be the right time for me to step down as CEO once a suitable successor has been found. I am very confident that the successful progression of our products, programs and commercial partnerships will continue, which will in turn deliver important medical outcomes and commercial returns. I would especially like to thank the Board and senior executive team as well as our highly skilled and committed Starpharma employees and the Company’s many long-term shareholders. I look forward to working with my successor, once appointed, for an effective handover and to following the Company’s success in the future.” The Board has engaged executive search firm Heidrich & Struggles to conduct a global search for a new CEO who will lead the Company’s next phase of commercial development, building on Jackie’s legacy. About Starpharma Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a biopharmaceutical company, focussed on the development of pharmaceutical and medical products for unmet patient needs, including in the areas of oncology and infectious diseases. Starpharma’s innovative technology is based on proprietary polymers called dendrimers, which are precise, synthetically manufactured, nanoscale molecules. The unique properties of dendrimers – including their size, structure, high degree of branching, polyvalency, and water solubility – are advantageous in medical and pharmaceutical applications. Starpharma uses its dendrimer technology to develop novel therapeutics and to improve the performance of existing pharmaceuticals. Starpharma’s portfolio includes multiple clinical stage oncology products, which utilise its Dendrimer Enhanced Product (‘DEP®’) drug delivery technology; and marketed products, including VIRALEZE™ and VivaGel® BV, which utilise SPL7013, a proprietary dendrimer with antimicrobial properties. Starpharma’s DEP® drug delivery platform is being used to enhance the effectiveness of existing and novel therapies and to reduce drug-related toxicities through controlled and specified drug delivery. In addition to Starpharma’s internal DEP® programs, Starpharma has multiple DEP® partnerships with international biopharmaceutical companies including AstraZeneca (oncology); MSD (antibody drug conjugates); Chase Sun (anti-infectives); and other world leading pharmaceutical companies. Due to the broad applicability and optionality of Starpharma’s DEP® platform, partnered DEP® programs have the potential to generate significant future milestones and royalties. Starpharma’s topical antiviral nasal spray, VIRALEZE™, is now registered in more than 35 countries*, including in Europe, in the U.K., and in Asia. Starpharma’s novel non-antibiotic vaginal gel, VivaGel® BV, for treatment of bacterial vaginosis (BV) and prevention of recurrent BV, is registered in more than 45 countries, including in the UK, in Europe, in Southeast Asia, South Africa, Australia and New Zealand. * Note: VIRALEZE™ is not approved for use or supply in Australia. Starpharma.com | Twitter | LinkedIn Media: Sumit Media Grant Titmus Mob: +61 419 388 161 grant@sumitmedia.com.au Starpharma Holdings Limited Dr Jackie Fairley, Chief Executive Officer Justin Cahill, CFO and Company Secretary +61 3 8532 2704 investor.relations@starpharma.com 4-6 Southampton Crescent Abbotsford Vic 3067 Disclosure This ASX Announcement was authorised for release by the Chair, Mr Rob Thomas. Forward Looking Statements This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product. 2